Axel Hegele

2.6k total citations
134 papers, 1.9k citations indexed

About

Axel Hegele is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Axel Hegele has authored 134 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Surgery, 59 papers in Pulmonary and Respiratory Medicine and 31 papers in Oncology. Recurrent topics in Axel Hegele's work include Bladder and Urothelial Cancer Treatments (32 papers), Renal cell carcinoma treatment (26 papers) and Urologic and reproductive health conditions (16 papers). Axel Hegele is often cited by papers focused on Bladder and Urothelial Cancer Treatments (32 papers), Renal cell carcinoma treatment (26 papers) and Urologic and reproductive health conditions (16 papers). Axel Hegele collaborates with scholars based in Germany, United States and France. Axel Hegele's co-authors include Rainer Hofmann, P. Olbert, Axel Heidenreich, Zoltán Varga, Andres Jan Schrader, Rolf von Knobloch, Peter Barth, Carsten‐Henning Ohlmann, J. Kröpf and Jörg Hänze and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Endocrinology.

In The Last Decade

Axel Hegele

121 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Axel Hegele Germany 23 709 671 600 409 253 134 1.9k
Takashi Ohigashi Japan 25 926 1.3× 395 0.6× 547 0.9× 463 1.1× 216 0.9× 94 2.1k
Guido Seitz Germany 24 907 1.3× 681 1.0× 530 0.9× 380 0.9× 240 0.9× 138 2.1k
Kutsal Yörükoğlu Türkiye 22 596 0.8× 511 0.8× 459 0.8× 269 0.7× 149 0.6× 144 1.6k
Yasushi Nakai Japan 22 698 1.0× 761 1.1× 462 0.8× 448 1.1× 122 0.5× 192 1.9k
Francesca Sanguedolce Italy 28 744 1.0× 701 1.0× 700 1.2× 547 1.3× 180 0.7× 167 2.3k
Sophie Ferlicot France 29 825 1.2× 628 0.9× 902 1.5× 454 1.1× 248 1.0× 124 2.5k
Yutaka Horiguchi Japan 26 758 1.1× 785 1.2× 579 1.0× 712 1.7× 157 0.6× 67 2.3k
Constantinos Constantinides Greece 24 623 0.9× 581 0.9× 422 0.7× 220 0.5× 242 1.0× 105 1.7k
Yun‐Sok Ha South Korea 26 1.0k 1.4× 979 1.5× 1.2k 2.0× 451 1.1× 172 0.7× 194 2.8k
Werner de Riese United States 22 851 1.2× 432 0.6× 720 1.2× 244 0.6× 221 0.9× 89 1.7k

Countries citing papers authored by Axel Hegele

Since Specialization
Citations

This map shows the geographic impact of Axel Hegele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Hegele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Hegele more than expected).

Fields of papers citing papers by Axel Hegele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Hegele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Hegele. The network helps show where Axel Hegele may publish in the future.

Co-authorship network of co-authors of Axel Hegele

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Hegele. A scholar is included among the top collaborators of Axel Hegele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Hegele. Axel Hegele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hegele, Axel, et al.. (2024). Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. Journal of Cancer Research and Clinical Oncology. 150(9). 414–414. 2 indexed citations
2.
Bamias, Aristotelis, Axel Hegele, Jacques Médioni, et al.. (2019). Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. Critical Reviews in Oncology/Hematology. 140. 80–87. 4 indexed citations
3.
Jung, Michaela, Frederik C. Roos, Roman A. Blaheta, et al.. (2019). NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells. Journal of Cancer Research and Clinical Oncology. 145(6). 1405–1416. 14 indexed citations
4.
Hänze, Jörg, Friederike Kessel, Pietro Di Fazio, Rainer Hofmann, & Axel Hegele. (2018). Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells. Biomedicine & Pharmacotherapy. 106. 316–325. 8 indexed citations
5.
Rexin, Peter, Jörg Hänze, Hendrik Heers, et al.. (2018). The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer. Anticancer Research. 38(5). 2749–2754. 11 indexed citations
6.
Heers, Hendrik, et al.. (2015). Lymphoceles Post-Radical Retropubic Prostatectomy: A Retrospective Evaluation of Epidemiology, Risk Factors and Outcome. Urologia Internationalis. 95(4). 400–405. 15 indexed citations
7.
Hegele, Axel, et al.. (2013). Nachwuchs gewinnen – aber wie?. Der Urologe. 53(2). 236–240. 3 indexed citations
8.
Hegele, Axel, et al.. (2012). Multiparametrisches MRT, Elastographie, kontrastmittelverstärkter Ultraschall. Der Urologe. 51(9). 1270–1277. 1 indexed citations
9.
Alkatout, İbrahim, et al.. (2011). Impact of robot-assisted radical prostatectomy on health-related quality of life in patients with lower urinary tract symptoms. International Journal of Urology. 2 indexed citations
10.
Hegele, Axel, et al.. (2011). Predictors of Spermatic Cord Torsion—Clinical Presentation and Intraoperative Findings. Open Journal of Urology. 1(4). 81–85. 2 indexed citations
11.
Hegele, Axel, et al.. (2011). Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clinica Chimica Acta. 413(1-2). 143–149. 97 indexed citations
12.
Schnabel, Michael, et al.. (2009). Die transorale Vertebroplastie. Der Unfallchirurg. 112(4). 426–432. 1 indexed citations
13.
Schrader, Andres Jan, P. Olbert, Axel Hegele, et al.. (2008). Incidence and long-term prognosis of papillary renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 135(6). 799–805. 20 indexed citations
14.
Naumann, Carsten Maik, İbrahim Alkatout, Axel Hegele, et al.. (2008). Lymph‐node metastases in intermediate‐risk squamous cell carcinoma of the penis. British Journal of Urology. 102(9). 1102–1106. 17 indexed citations
15.
Geyer, V., et al.. (2007). Emphysematöse Zystitis: Ein Fallbericht. Urologe A. 46(1). 66–68. 1 indexed citations
16.
Olbert, P., Alexander H. Dalpke, Klaus Heeg, et al.. (2004). 823 Antineoplastic effect of immunostimulative DNA (CPG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. European Urology Supplements. 3(2). 208–208. 2 indexed citations
17.
Hegele, Axel, et al.. (2003). Plastisch-chirurgisches Therapiekonzept des infizierten Sinus pilonidalis. Der Chirurg. 74(8). 749–752. 13 indexed citations
18.
Hegele, Axel, Axel Heidenreich, Zoltán Varga, et al.. (2003). Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Urological Research. 30(6). 363–366. 22 indexed citations
19.
Varga, Zoltán, Axel Hegele, T. Stief, Axel Heidenreich, & Rainer Hofmann. (2002). Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?. Urological Research. 30(2). 122–125. 11 indexed citations
20.
Hegele, Axel, et al.. (2002). Isolierte Nebenhodentorsion bei Hoden-Nebenhoden-Dissoziation. Der Urologe. 41(4). 364–365. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takashi Ohigashi Breakdown of academic impact, for papers by Guido Seitz Breakdown of academic impact, for papers by Kutsal Yörükoğlu Breakdown of academic impact, for papers by Yasushi Nakai Breakdown of academic impact, for papers by Francesca Sanguedolce Breakdown of academic impact, for papers by Sophie Ferlicot Breakdown of academic impact, for papers by Yutaka Horiguchi Breakdown of academic impact, for papers by Constantinos Constantinides Breakdown of academic impact, for papers by Yun‐Sok Ha Breakdown of academic impact, for papers by Werner de Riese
Rankless by CCL
2026